Pharmaceuticals

Company                                    Sales( Figurein Crores)                        Adj.PAT(Figure in Crores)

Chg%                                                      Chg%
Q3FY21E (YoY) (QoQ) Q3FY21E (YoY) (QoQ)
Abbott India 1,143 6 8.4 200 7.3 10.9
Alembic Pharma 1,441 19.2 -1.1 255 9 -23.4
Alkem 2,364 8.3 0.1 389 1.9 -17.5
Aurobindo Pharma 6,310 7 (-2.7) 789 11.3 -1.6
Biocon 1,948 11.4 11.6 240 18.3 41.7
Cadilla 3,848 6.2 0.4 450 25.4 -23.4
Cipla 4,803 9.9 -4.7 543 40.2 -18.3
Divi’s Lab 1,671 19.6 -4.5 456 26.9 -12.3
Dr.Reddy’s 5,007 14.2 2.3 619 18.4 -25.5
Glenmark 2,856 4.4 -3.3 218 14.1 -19.7
JB Chemicals 518 20.7 16.7 90 35.3 21.3
Lupin 4,011 6.4 4.6 366 236.1 73.6
Shilpa Medicare 257 8.7 -7.7 39 -29.7 -14.8
Sun Pharma 8,862 8.7 3.6 1,090 19.3 -31.5
Torrent pharma 2,054 4.5 1.8 339 35 9.3

(Source: AWACS. ICICI Securities, Bloomberg,IBEF)

Key Points:

  • India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the
  • In Q3FY21, The Indian Pharma Market has seen the growth of 6.4% in value and declined by 1.9% in volumes. on the other hand, Prices and new introductions witnessed the growth of 4.9% and 3.4%
  • Data for Dec’20 shows Indian Pharma Market (IPM) had a growth rate of 3.1% in value terms over the year (MAT Dec’20). Adjusting for seasonality and free samples, industry grew at similar levels (3.2%) for the 12 months ended Dec’20. Chronic products portfolio grew at 8.5%, while acute portfolio remained flattish with a growth of 0.4% over the year in MAT

Key Categories Performance (MAT Dec, 2020)

  • Anti-infectives declined 2.1%, while respiratory grew 0.2%,
  • Chronic products segment continued to drive sales in the markets growing at an overall 8.5% rate with 13.4% YoY growth in cardiovascular and 7.8% YoY growth in anti-diabetic
  • Gastro-intestinal and derma sales grew 2.7% and 0.7% YoY, respectively, while VMN and Neuro/CNS grew 6.6% and 5.4%,
  • Pain/Analgesics, anti-neoplastics and gynaec declined 2.8%, 3.2% and 3.5% YoY,
  • Urology grew 7.8%, while ophthalmology declined 8.0% YoY, respectively

Companies to Consider: 

JB Chemicals: In Q3FY21, It is expected that JB chemicals would be seen an improvement of 16.7% in sales Q-o-Q that would result Growth in PAT of 21.3%. Q-o-Q

Biocon: with new product launches in the US. In Q3FY21, It is expected that Biocon could register the growth in sales of 11.6% Q-o-Q that would result Growth in PAT of 41.7%. Q-o-Q

Divi’s Lab: Led by strong demand for APIs from India. In Q3FY21,It is expected that company would report growth in sales and PAT of 19.6% Y-o-Y and 26.9% Y-o-Y

DISCLOSURE IN PURSUANCE OF SECTION 19 OF SEBI (RA) REGULATION 2014

Elite Wealth Ltd. does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Advisors Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as read more

For Daily Share Market Updates, Daily debt market review, Market Research Analysis reports, Weekly Techno-Funda Report, Fundamental Analysis Report, Monthly Recommended stock Picks, Equity Trading Tips, Upcoming IPO/NFO/Bonds/Ncd’s updates & other related information Subscribe our research plan